Background: Patients with Chronic Obstructive Pulmonary Disease (COPD) are at higher risk of developing Community-Acquired Pneumonia (CAP) than patients in the general population. However, no studies have been performed in general practice assessing longitudinal incidence rates for CAP in COPD patients or risk factors for pneumonia onset. Methods: A cohort of COPD patients aged 45 years, was identified in the General Research Practice Database (GPRD) between 1996 and 2005, and annual and 10-year incidence rates of CAP evaluated. A nested case-control analysis was performed, comparing descriptors in COPD patients with and without CAP using conditional logistic regression generating odds ratios (OR) and 95% confidence intervals (CI associated with CAP were co-morbidities including congestive heart failure (OR 1.4, 95% CI 1.2 e1.6), and dementia (OR 2.6, 95%CI 1.9e3.). Prior severe COPD exacerbations requiring hospitalization (OR 2.7, 95% CI 2.3e3.2) and severe COPD requiring home oxygen or nebulised therapy (OR 1.4, 95% CI 1.1e1.6) were also significantly associated with risk of CAP. Conclusion: COPD patients presenting in general practice with specific co-morbidities, severe COPD, and age >65 years are at increased risk of CAP. ª
Introduction
Community-acquired pneumonia (CAP) has been associated with risk of hospitalization and mortality in patients with chronic obstructive pulmonary disease (COPD).
1e4 COPD patients with CAP have been shown to have worse clinical outcomes compared to similarly aged CAP patients without COPD in terms of CAP severity, intensive care admissions, and mortality. 5, 6 This excessive CAP burden among COPD patients contributes to the overwhelming hospital and societal costs. 7 Most studies assessing co-morbid COPD and CAP have focused on hospitalized patients, with small convenience samples, which were not representative of national populations. Study designs were limited to prevalence assessment or short-term follow up. 1, 3, 6 Observational and randomized clinical trials, reported an increased risk of CAP in COPD patients exposed to inhaled corticosteroids (ICS). 8e16 These studies, however, did not usually report additional risk factorsfor CAP, such as other co-morbidities, clinical characteristics, and consulting history. Accurate assessment of risk of CAP in COPD patients will improve awareness of clinically relevant risk factors. This should assist with timely diagnosis and treatment to reduce the CAP burden within the COPD population Understanding factors which are both associated with and/or predict CAP incidence requires comparing COPD patients with and without CAP in a large clinical population.
We performed a longitudinal evaluation of a representative sample of the UK general practice population to assess the incidence, natural history, and risk factors for CAP in a COPD population.
Materials and methods

Study design and patient population
Data were obtained from the General Practice Research Database (GPRD) for the observation period between January 1st, 1996 and December 31st, 2005. The GPRD contains complete data on more than 5 million patients from England and Wales from several hundred general practices. These data are representative of the age and gender structure in the UK general population 17 and accurately reflect clinical reported respiratory disease diagnosis. 18 This study used a population-based retrospective cohort design to estimate incidence and natural history of CAP within the prevalent COPD population. The cohort selection evolution is described in Fig. 1 . COPD patients were defined as aged 45 years and over with a COPD diagnosis recorded in their medical record at least once during the observation period and who had a subsequent COPD related prescription (i.e. bronchodilators, inhaled or oral corticosteroids) within 1 year from the first medical COPD diagnosis. Additionally, patients had at least 24 months of total history in the GPRD, with 12 months of this history after the COPD diagnosis date to allow reasonable time for assessment of the natural history of the disease. Patients were excluded if they had a medical code indicating a serious lung disease j that would have interfered with COPD outcomes. Patients were required to have a minimum of one record of any diagnosis or medication per year for any cause. Other censoring events included death, transferring out of the practice, and end of follow up.
We implemented a nested case control design to compare differences in clinical characteristics and medication exposure from time of first COPD diagnosis in patients by subsequent CAP status. Patients were matched using a 1:5case to control ratio on length of follow up. Matching by time ensured that patients had a similar length of history for covariate collection and a similar probability of CAP diagnosis.
Outcome definition
The primary outcome was aphysician-recorded diagnosis of CAP identified using a set of "Read" codes (diagnosis coding system used by the GPRD). A single episode of CAP was defined as taking up to 10 weeks to resolve; a minimum of 14 days without antibiotics or relevant health-care visits separated one episode from another. See Appendix A regarding criteria for longitudinal CAP events.
Covariates
Age, body mass index (BMI) and smoking status were defined at the first CAP episode and were based on the most recent measurement prior to the this episode. Further, COPD treatment history, vaccination related to pneumonia (pneumococcal and influenza), number of GP visits, number of referrals to a pulmonologist, COPD exacerbations (see Appendix B for definition), and respiratory medications and treatments previously suggested to be associated with CAP incidence in the literature (i.e. statins, ACE-inhibitors and immunosuppressive treatment including antiretroviral medications) were counted within 12 months prior to the first CAP episode 19e21 . Co-morbid conditions were defined based on diagnosis codes recorded during the observation period until the first CAP episode. All diseases contained in the modified Charlson co-morbidity index, in addition to depression, anxiety and asthma were included. 22 COPD severity was defined according to prior published literature 23 since lung function data was not yet recorded within the GPRD during the observation period.
Statistical analysis
Incidence and recurrence of CAP and all-cause mortality were estimated for the observation period. Annual incidence rates based on calendar time were calculated by dividing the number of patients with CAP diagnosed within a specific year, by the total person-days of follow up within each calendar year. Days were counted from January 1st until the first date of the CAP episode. If no event occurred for a patient, the day contribution was 365. 25 . If an event crossed a calendar year, the event was included in the year with the episode start date. Period incidence (10 year incidence density, based on calendar time 1996e2005) was calculated by dividing the number of community-acquired pneumonia episodes by the total person-days of follow up. Multiple events were included for all patients and persondays ran from the end of one episode to the start of the next. For both objectives, descriptive statistics were performed and proportions were tested using the c 2 test and continuous variables using the Student's t-test. Multivariate conditional logistic regression modelling was used to assess risk factors associated with CAP. Due to the large number of variables only those significant at p < 0.05 in the group comparison were included in the final model. Final estimates are provided with 95% confidence limits. Analyses were conducted using SAS version 9 (SAS Institute, Cary, NC).
Results
The COPD cohort consisted of 40,414 adults aged 45 years and over. Cohorts characteristics are described in Table 1 . Men represented 52% of the cohort and approximately 40% a Mild patients Z not treated during observation, moderate patients Z regular COPD treatment (2 prescriptions of the same drug group within six months), severe patients Z oxygen or nebulised therapy prescriptions.
b Asthma history refers to at least one asthma diagnosis prior to the start of the individual's observation period (1st of January 1996 or any later start date in GPRD).
c Prior pneumonia refers to an historical episode of community-acquired pneumonia recorded prior to the start of the individual's observation period. j Cystic fibrosis, interstitial lung disease, pulmonary fibrosis, lung agenesis, major lung surgery (transplantation, resection, lobectomy). of patients were current smokers. A total of 3149 COPD patients had suffered at least one CAP episode during the observation period (8%). Of those that experienced CAP, the majority (92%) had only one episode during 10-years of observation. Between 1996 and 2005, 10,390 (25.1%) COPD patients died in the cohort; overall 20% (n Z 2068) had suffered CAP during the observation period. When splitting COPD patients by their event of CAP, sixty percent of those with CAP episode during the observation period died as compared to 22% of those without a CAP episode.
The 10-year incidence rates for the observation period are shown in Table 2 . The incidence of CAP was most strongly associated with age 80þ, history of asthma, history of pneumonia, and COPD severity. The 1 year incidence of CAP was highest in severe COPD patients showing fluctuation in rate over time, with a stable rate for mild and moderate patients, as illustrated in Fig. 2 . Use of influenza vaccine appears protective; rates of CAP in unvaccinated patients were significantly higher than in vaccinated patients for some years of follow up, [ Fig. 3 ].
In the case control analysis, a total of 1469 COPD patients with at least one diagnosed CAP episode between 1996 and 2005 were matched on length of time in the database to 7345 COPD patients without CAP. COPD patients with CAP consistently showed evidence of a more severe disease, with more co-morbidities, and higher frequency of moderate and severe COPD exacerbation (Table 3) . Those with CAP were more frequent users of ACE-inhibitors, were older, and had higher utilization of GP care. Influenza vaccine rates were high in both groups. Prevalence of COPD medications were similar in terms of any ICS use, but the COPD patient with CAP group had higher use of LABA. a Asthma history refers to at least one asthma diagnosis prior to the start of the individual's observation period (1st of January 1996 or any later start date in GPRD).
b Prior pneumonia refers to an historical episode of CAP recorded prior to the start of the individual's observation period (1st of January 1996 or any later start date in GPRD).
c Mild patients Z not treated during observation period, moderate patients Z regular COPD treatment (2 prescriptions of the same drug group within 6 months), severe patients Z oxygen or nebulised therapy prescriptions (adapted from Soriano et al. 18 ). Figure 2 The 1-year incidence rates of community-acquired pneumonia episodes (1996e2005) stratified by COPD severity. Legend: mild patients Z not treated during observation period, moderate patients Z regular COPD treatment (2 prescriptions of the same drug group within six months), severe patients Z oxygen or nebulised therapy prescriptions (adapted from Soriano et al. 18 ). a Mild patients Z not treated, moderate patients Z regular COPD treatment (2 prescriptions of the same drug group within 6 months), severe patients Z oxygen or nebulised therapy prescriptions (adapted from Soriano et al. 18 ). b Descriptor measured in the 12 months prior to the first CAP episode. c Moderate exacerbations were defined as: (1) treatment with oral steroids and antibiotics within 14 days time interval; (2) COPD exacerbation diagnosis, or (3) acute bronchitis diagnosis.
Risk estimates for CAP diagnosis in primary care based on multivariate regression modelling are shown in Table 4 . COPD patients age 65e79 and age 80 and older had increasingly higher risk of CAP than younger patients. Higher BMI appears protective against CAP compared to normal weight. Current smoking status was not associated with CAP incidence. Severe COPD was associated with an increased risk of CAP, but risk among moderate COPD was not significantly different from mild COPD. Some co-morbid conditions were significantly associated with of CAP, namely congestive heart failure (OR 1.4 95% CI 1.2; 1.6), dementia (OR 2.6 95% CI 1.9; 3.8), peptic ulcer (OR 1.2 95% CI 1.1; 1.4), peripheral vascular disease (OR 1.3 95% CI 1.1; 1.6) and connective tissue disease (OR 1.2 95% CI 1.0; 1.3). Prior hospitalizations for COPD exacerbation and moderate COPD exacerbation were also significantly associated with CAP, as was the highest category of GP visit frequency in the prior year(>15 visits).
Death occurred in 869 patients with CAP (59%) and in 2974 (41%) patients without CAP (Odds Ratio 2.1; 95% CI 2.2e2.7). The average time to death was comparable between cases and controls (372 days vs. 345 days, respectively).
Discussion
The study results present the first evaluation of pneumonia incidence, longitudinal patterns and risk factors as recorded in UK general practice. Compared to other studies conducted in the UK general practice, which considered all adult patients registered in primary care, the risk of CAP in a Mild patients Z not treated, moderate patients Z regular COPD treatment (2 þ prescriptions of the same drug group within 6 months), severe patients Z oxygen or nebulised therapy prescriptions (adapted from Soriano et al. 18 ). b Moderate exacerbations were defined as: (1) treatment with oral steroids plus antibiotics within 14 days time interval; (2) COPD exacerbation diagnosis, or (3) acute bronchitis diagnosis.
c All patients were required to have at least one visit to a GP in 12 mo prior to the event.
COPD is almost 10-fold higher. 24, 25 Further, this study showed that 8% (3149) of the COPD cohort (40,414) suffered an occurrence of one or more CAP episodes during 10-years of follow up. 92% of these patients had only one episode equating to an incidence rate of 22.4 per 1000 person years. Significant risk factors associated with CAP included older age, COPD severity, history of CAP episodes prior to start of the observation period, and certain co-morbid conditions including congestive heart failure, reflux disease and dementia.
Several methodological issues could have affected the results of this study. First, we were unable to validate the CAP diagnosis listed in the patient record by chest radiograph since these data were from a large retrospective cohort. Previous studies have shown that written clinical diagnosis in the GPRD is accurate in terms of the physician's assessment of the disease state, and GPRD diagnosis rates for pneumonia were similar to the 4th Morbidity Survey in General Practice consultation rates. 20, 26 However, the sensitivity and specificity of clinical variables are presumably low, and therefore establishing the CAP diagnosis on clinical observations alone may not be fully reliable. Second, we defined a CAP episode length by expert clinical knowledge, due to limited information in the published data. 27 Lastly, we matched patients with CAP to those without CAP based on time spent in the database. Matching on other criteria, such as age or gender, would have limited our ability to statistically analyze the differences in these covariates between groups.
A third potential limitation of this study design relates to our definition of COPD. Because of the low incidence of CAP, we intentionally selected a longer period of 10-years to observe any trends over time and to collect a sufficient number of events to enable a robust multivariate analysis to characterizefactors associated with CAP. A programme incentivising administration and collection of COPD indices in the English primary (Quality Outcomes Framework) did not come into practice until April 1, 2004 . There are two factors supporting the use of medical diagnosis only based COPD ascertainment: (1) the codes used in this study were derived based on the validation study by Soriano and colleagues 18 and (2) an almost identical list of medical diagnoses has been used elsewhere in studies of COPD in the UK primary care. 28 Further, we observed about 20% of COPD patients in GPRD labelled as non-smokers. This findings is in agreement with the prevalence of non-smoking among COPD patients as reported by Schneider and colleagues (22%). 29 It is also consistent with the findings of population-based studies of airway obstruction, namely the BOLD study. 30 But, we can never be confident the patients we describe as non-smokers are true never smokers. Indeed, the small numerical increase in the frequency of CAP in the non-smoker group may indicate a possibility that some patients were in an advanced stage of COPD and recently changed their smoking, which may not be fully recorded.
The large size of the COPD population allowed for increased precision of CAP incidence rates. The 10-year CAP incidence rate in this study was 22.4 per 1000 person years. A randomized clinical trial by Merino-Sanchez et al 31 reported a rate of 55.1 per 1000 person years during 3 years of follow up in Spain; however, these subjects were more likely to have more severe COPD than our general practice cohort. In the 3 year TORCH study, pneumonia incidence rate varied by treatment arm from 30 to 55 events per 1000 treatmentyears; however, again this population differed substantially from COPD patients managed in the community. 12 Our results are supported by other reports of CAP being associated with older age, lower BMI, and deteriorated lung function, which correlates to the proxy severity categories of oxygen and nebulised therapy use in our GPRD study. 12, 32 General risk factors for CAP, identified in previous studies, mainly during a hospitalization for CAP, include age 65þ, former or current smoking, male sex, and co-morbidities such as chronic heart failure, advanced chronic obstructive pulmonary disease, neurological diseases, and liver cirrhosis 33e36 . Age may show a positive association with disease incidence because practitioners may more readily diagnose pneumonia in an older patient, where prevalence is known to be higher. In our study, current smoking was not associated with CAP, while never and unknown smoking status were associated with CAP in a univariate relationship. No association with smoking was observed in a multivariate model. These associations could be due to inaccurate recording of current smoking status, severe COPD caused by occupational exposures or alpha1-antitrypsin deficiency. Further, confounding by disease severity may impact this observation, where COPD patients with more severe disease tend to become former smokers following smoking cessation. A 'paradoxical' lack of an association of CAP occurrence with obesity has been observed elsewhere. 12, 37 We can only speculate that this observation can be a result of an increased readiness of GPs to diagnose CAP in underweight patients. We did not replicate an earlier finding of an association of diabetes mellitus with an increased risk of CAP. 32 This observation can be explained as due to selection of a different population (the earlier study employed hospitalized pneumonia definition only), potential misdiagnosis of diabetes in primary care, or correlation of several diagnoses occurring in the same patients such that any diabetes effect would be mostly explained by other co-diagnoses.
During the 10-year observation period, 8% of patients had one or more episodes of CAP, which probably indicates impaired host defence in a minority of patients with COPD. This occurrence is similar to previously reported incidence of 9% for recurrent (CAP) requiring hospitalization. 38 Overall, the majority of COPD patients were at low risk of opportunistic infection. Congestive heart failure (CHF), peripheral vascular disease, connective tissue disease, peptic ulcer and dementia were significantly associated with CAP incidence. CHF failure is commonly found in hospitalized COPD patients with and without CAP 2, 5, 39 and is a predictor of mortality from pneumonia. 6 CHF in COPD patients may be an outcome of an overall systemic inflammatory phenotype as recently suggested in the literature and further research is required in this area. 40 Dementia is increasingly prevalent in older adult patients with CAP, since they share the common risk pattern of nonlinear increase with age. Moreover, the use of sedative medications and issues with swallowing may contribute to impact of dementia in these patients. 41 These factors may apply to this cohort of COPD patients, which has a high proportion of patients over age 65.
Medications used to treat some co-morbid conditions, such as peptic ulcer, may be significantly associated with incidence of infection. This observed effect may be due to current use of proton pump inhibitors (PPI) to treat peptic ulcer rather than the condition itself. Gulmez et al. reported increased risk of CAP in the general population (OR 1.5 95% CI 1.3e1.7) among PPI users. 42 The authors stated that recent initiation of treatment with PPI's (0e7 days prior to CAP episode), resulted in a strong association with CAP (OR 5.0; CI 2.1e11.7). These findings warrant further research into co-morbidity and concurrent medication risk in COPD patients who develop CAP.
Adjusted multivariate models did not report a significant association between vaccine use and reduction in risk for CAP. These results may be due to under-ascertainment of vaccine uptake in the database due to (i) the vaccine receipt not limited to GP's office and may not be routinely listed in personal prescribing variable listings or (ii) lower uptake or provision of vaccine programmes in the 1990s. Results from previous research on this topic have been mixed. Lee and colleagues reported the risk of CAP hospitalization fell after vaccination from 8.0 (CI 4.4e14.5) to 3.9 (CI 2.6e5.9). 43 However, Skull and colleagues reported no benefit from use of either vaccine to prevent CAP in the general population. 44 Regarding respiratory medications, the results suggested that ICS use was similar in both COPD patients with and without pneumonia, but LABA was used more often by patients with pneumonia. Confounding by severity, with more severe COPD patients at higher risk of CAP being prescribed LABA in addition to ICS, may explain these results. Use of ICS, whilst restricted to an add-on therapy to a long-acting bronchodilator in moderate to severe patients in the guidelines, 45 may be prescribed across all levels of severity in general practice, particularly in those patients with prior asthma diagnosis of which there were 45% in this population. This use of ICS in COPD supports previous findings of a UK study where CAP patients who were admitted to the hospital from the community and were users of ICS had diagnoses of chronic bronchitis and/or asthma. 33 In conclusion, our study indicated that, among COPD patients treated in UK general practice, the incidence of CAP was increased in sub-populations characterized by specific risk factors, particularly older age, higher COPD severity, prior CAP episodes, and some co-morbid conditions.
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What is the current scientific knowledge on the subject?
Community-Acquired Pneumonia significantly increases morbidity and mortality risk, frequently accounting for hospital admissions, among patients diagnosed with Chronic Obstructive Pulmonary Disease. Nevertheless, its incidence and predisposing factors have not been well documented in COPD patient populations.
What this study adds
This population-based study suggests that CommunityAcquired Pneumonia, as diagnosed in primary care, occurs commonly in COPD patients, with easily recognizable risk factors of older age, severe COPD, prior hospitalization for COPD and certain co-morbidities (diagnosis of heart failure or dementia) e an implication for targeting risk groups in primary care for more careful monitoring and management.
Conflict of interest statement
Hana Müllerova and Kourtney Davis are employees of GlaxoSmithKline R&D and own shares and stok option of GlaxoSmithKline plc. Chuba Cigbo has not conflict of interest.
Gerry Hagan is a retired employee of GlaxoSmithKline and continues work as a Consultant to various pharmaceutical companies, including GlaxoSmithKline. He has shares in and receives a pension from GSK.
Marc Miravitlles has received payments for speaking at scientific meetings and participating in advisory boards by Boehringer Ingelheim, Pfizer, Nycomed, Merck Sharp & Dohme, Novartis, Bayer Schering Pharma, and for participating in advisory boards by Almirall and GlaxoSmithKline. Jadwiga WedzichaI has received honoraria for lectures and advisory boards from GlaxoSmithKline. Her institution has also received research grant funding for trials and observational studies (ECLIPSE) from GlaxoSmithKline.
Mark Woodhead has received financial support for travel and accommodation to attend the European Respiratory Society meeting in 2010, has acted as a paid Consultant to Astellis and is a paid member of a data monitoring committee for an ongoing clinical trial run by Pfizer.
